Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Hagop M. Kantarjian, Guillermo Garcia‐Manero et al.|Cancer Discovery|2018Cited by 570
Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignanciesCourtney D. DiNardo, Marina Konopleva, Farhad Ravandi et al.|American Journal of Hematology|2017Cited by 437
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Naval Daver et al.|Nature Medicine|2023Cited by 372
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaAndy G.X. Zeng, John E. Dick, Suraj Bansal et al.|Nature Medicine|2022Cited by 338
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Curtis A. Lachowiez et al.|Journal of Clinical Oncology|2021Cited by 333